> ## Content Index
> Fetch the complete content index at: https://www.healthdatacon.io/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Program Fast-Tracks Devices for Unmet Medical Needs
- URL: https://www.healthdatacon.io/articles/fda-program-fast-tracks-devices-for-unmet-medical-needs/
- Published: 2015-04-10T11:51:15.000Z
- Updated: 2026-11-10T07:46:18.000Z
- Description: The Food and Drug Administration is fast-tracking qualifying medical devices to patients with life-threatening or irreversibly debilitating conditions that lack treatment and diagnostic options.
- Author: Greg Slabodkin
- Tags: Health IT

The Food and Drug Administration is fast-tracking qualifying medical devices to patients with life-threatening or irreversibly debilitating conditions that lack treatment and diagnostic options.  
  
The FDAs new Expedited Access Pathway (EAP) program covers certain medical devices that demonstrate potential to address unmet medical needs that are subject to pre-market approval applications (PMA) or are eligible for *de novo* requests. FDA works with device sponsors to try to reduce the time and cost from development to marketing decision without changing the PMA approval standard of reasonable assurance of safety and effectiveness, the standards for granting *de novo* requests, or for the FDA standard of valid scientific evidence.  
  
According to Jeffrey Shuren, M.D., director of FDAs Center for Devices and Radiological Health, the program will launch on April 15 when the agency will begin to accept requests for EAP designation. Shuren said his staff will work collaboratively with developers of such devices earlier and more often including the creation of a Data Development Plan that provides predictability and leverages post-market data collection.  
  
**Also See**: [FDAs Sentinel System Harnesses Big Data to Monitor Medical Products](https://www.healthdatacon.io/content/files/2026/11/fda-sentinel-system-harnesses-big-data-to-monitor-medical-products-49980-1-3.html)  
  
The Data Development Plan will shift premarket data collection to the post-market setting, to the extent appropriate, taking into account the public health benefit of these devices, while still meeting the U.S. approval standard of reasonable assurance of safety and effectiveness, writes Shuren in a blog. The premarket data must be adequate to support FDAs high standard for premarket review but can include data based on an intermediate endpoint or a surrogate endpoint reasonably likely to predict clinical benefit.  
  
To qualify for the program, a device must meet at least one of the following criteria:  
  
\*No appropriate alternative treatment or means of diagnosis exists.  
  
\*Represents a breakthrough technology that provides a clinically meaningful advantage over existing legally marketed technology.  
  
\*Offers significant, clinically meaningful advantages over existing legally marketed alternatives.  
  
\*The availability of the device is in the best interest of patients.  
  
FDA has [released guidance](http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM393994.pdf?ref=healthdatacon.io) on balancing pre-market and post-market data collection that describes the circumstances under which post-market data collection is appropriate for PMAs and whether or not they meet the criteria for the EAP.  
  
If, after careful analysis, FDA determines that some data can be collected after the device is on the market, then patients in need will benefit sooner, according to Shuren. A few of the factors that can enter into this analysis include a low probability of serious harm, a high likelihood that post-market surveillance can quickly identify instances of serious patient harm and a high likelihood that post-market data collection will be completed in a timely manner.